Uxin Limited (NASDAQ:UXIN) Looks Just Right With A 29% Price Jump

Uxin Limited (NASDAQ:UXIN) shares have had a really impressive month, gaining 29% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 25% in the last twelve months. After such a large jump in price, when almost half of the companies in the United States' Specialty Retail industry have price-to-sales ratios (or "P/S") below 0.5x, you may consider Uxin as a stock probably not worth researching with its 1.8x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. See our latest analysis for Uxin NasdaqGS:UXIN Price to Sales Ratio vs Industry December 31st 2025 What Does Uxin's P/S Mean For Shareholders? Uxin certainly has been doing a good job lately as it's been growing revenue more than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock. Keen to find out how analysts think Uxin's future stacks up against the industry? In that case, our free report is a great place to start. What Are Revenue Growth Metrics Telling Us About The High P/S? In order to justify its P/S ratio, Uxin would need to produce impressive growth in excess of the industry. If we review the last year of revenue growth, the company posted a terrific increase of 73%. Revenue has also lifted 25% in aggregate from three years ago, mostly thanks to the last 12 months of growth. So we can start by confirming that the company has actually done a good job of growing revenue over that time. Looking ahead now, revenue is anticipated to climb by 88% per year during the coming three years according to the two analysts following the company. Meanwhile, the rest of the industry is forecast to only expand by 7.7% per year, which is noticeably less attractive. In light of this, it's understandable that Uxin's P/S sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future. The Final Word The large bounce in Uxin's shares has lifted the company's P/S handsomely. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator. As we suspected, our examination of Uxin's analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant. Having said that, be aware Uxin is showing 3 warning signs in our investment analysis, and 2 of those are a bit unpleasant. If these risks are making you reconsider your opinion on Uxin, explore our interactive list of high quality stocks to get an idea of what else is out there. Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTech